Hepatitis Monthly

Published by: Kowsar

FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection

Asadollah Mohammadi 1 , Nader Tajik 1 , * , Alireza Shah-Hosseini 1 , Seyed Moayed Alavian 2 , Zohreh Sharifi 3 and Lida Jarahi 4
Authors Information
1 Immunology Research Center (IRC), Iran University of Medical Sciences, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
4 Community Medicine Department, Addiction Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Hepatitis Monthly: October 2015, 15 (10); e26490
  • Published Online: October 10, 2015
  • Article Type: Research Article
  • Received: December 28, 2014
  • Revised: June 12, 2015
  • Accepted: August 12, 2015
  • DOI: 10.5812/hepatmon.26490

To Cite: Mohammadi A, Tajik N, Shah-Hosseini A, Alavian S M, Sharifi Z, et al. FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection, Hepat Mon. 2015 ;15(10):e26490. doi: 10.5812/hepatmon.26490.

Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Wei Y, Neuveut C, Tiollais P, Buendia MA. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol (Paris). 2010; 58(4): 267-72[DOI][PubMed]
  • 2. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010; 58(4): 258-66[DOI][PubMed]
  • 3. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005; 79(15): 9369-80[DOI][PubMed]
  • 4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-9[DOI][PubMed]
  • 5. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol. 2012; 55(4): 296-302[DOI][PubMed]
  • 6. Bertoletti A, Maini M, Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res. 2003; 60(2): 61-6[PubMed]
  • 7. Ichiki Y, He XS, Shimoda S, Ishibashi H, Keeffe EB, Rossaro L, et al. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev. 2005; 4(2): 82-95[DOI][PubMed]
  • 8. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999; 284(5415): 825-9[PubMed]
  • 9. Chen Y, Wei H, Gao B, Hu Z, Zheng S, Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepat. 2005; 12(1): 38-45[DOI][PubMed]
  • 10. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol. 2009; 130(1): 16-26[DOI][PubMed]
  • 11. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009; 86(3): 513-28[DOI][PubMed]
  • 12. Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta. 2013; 1832(7): 1061-9[DOI][PubMed]
  • 13. Jung M, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis. 2002; 2(1): 43-50[DOI]
  • 14. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010; 107(2): 798-802[DOI][PubMed]
  • 15. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996; 157(7): 2909-15[PubMed]
  • 16. Hayashi N, Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat. 1999; 6(5): 357-65[PubMed]
  • 17. Zou Y, Chen T, Han M, Wang H, Yan W, Song G, et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol. 2010; 184(1): 466-75[DOI][PubMed]
  • 18. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54(7): 1024-33[DOI][PubMed]
  • 19. Oksuz M, Akkiz H, Isiksal YF, Saydaogluc G, Serin M, Kayaselcuk F, et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol. 2004; 16(3): 341-5[PubMed]
  • 20. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol. 1994; 24(12): 3057-62[DOI][PubMed]
  • 21. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol. 1994; 6(10): 1567-74[PubMed]
  • 22. Huang QR, Morris D, Manolios N. Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997; 34(8-9): 577-82[DOI]
  • 23. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003; 170(1): 132-8[PubMed]
  • 24. Rivero M, Crespo J, Fabrega E, Casafont F, Mayorga M, Gomez-Fleitas M, et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat. 2002; 9(2): 107-13[PubMed]
  • 25. Lee JY, Chae DW, Kim SM, Nam ES, Jang MK, Lee JH, et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat. 2004; 11(2): 130-5[PubMed]
  • 26. Bortolami M, Kotsafti A, Cardin R, Farinati F. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat. 2008; 15(7): 515-22[DOI][PubMed]
  • 27. Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev. 2003; 2(1): 36-42[DOI]
  • 28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215[PubMed]
  • 29. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004; 96(13): 1030-6[PubMed]
  • 30. Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005; 100(6): 1322-9[DOI][PubMed]
  • 31. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007; 69(3): 227-35[DOI][PubMed]
  • 32. Marin LA, Muro M, Moya-Quiles MR, Miras M, Minguela A, Bermejo J, et al. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients. Tissue Antigens. 2006; 67(2): 117-26[DOI][PubMed]
  • 33. Aguilar-Reina J, Ruiz-Ferrer M, Pizarro MA, Antinolo G. The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. J Viral Hepat. 2005; 12(6): 568-73[DOI][PubMed]
  • 34. Zamani AG, Barlas IO, Durakbasi-Dursun G, Ural O, Erdal E, Yildirim MS. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection. Int J Immunogenet. 2013; 40(6): 482-7[DOI][PubMed]
  • 35. Jung YJ, Kim YJ, Kim LH, Lee SO, Park BL, Shin HD, et al. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology. 2007; 50(5): 369-76[DOI][PubMed]
  • 36. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997; 3(4): 409-13[PubMed]
  • 37. Balkow S, Kersten A, Tran TT, Stehle T, Grosse P, Museteanu C, et al. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol. 2001; 75(18): 8781-91[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader